ClinicalTrials.gg
TerminatedNCT01987492Updated Nov 10, 2026Results posted

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

A Phase 2 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Terminated at 45 sites in 15 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
Updated Nov 10, 2026Now TerminatedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
6th of 12
230 · median 224
Started
2014
with 2 others
Phase 2
7 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 9th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of OCS, among those with severe corticosteroid-dependent asthma. Prednisone/prednisolone will be the OCS therapy prescribed. Participants will be randomized to receive lebrikizumab or matching placebo for 44 weeks in a double-blind, placebo-controlled (DBPC) period. Those who complete the 44-week period may continue into a 32-week active treatment extension (ATE) period, during which all participants will receive lebrikizumab treatment. Following completion of the ATE period, participants who have both tolerated and derived benefit from treatment with lebrikizumab may continue their lebrikizumab treatment into a long-term extension (LTE) period. Participants will transition to 24 weeks of safety follow-up upon discontinuation of study drug.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe asthma despite intensive follow-up by an asthma specialist for >/=6 months prior to Visit 1
  • Baseline (FEV1) >/=40% of predicted prior to randomization
  • Receiving high doses of inhaled glucocorticosteroids at a total daily dose of >/=1500 micrograms (mcg) beclomethasone dipropionate or equivalent and long-acting beta-adrenoceptor agonist (LABA), with or without an additional controller, for at least 3 months prior to Visit 1
  • Chronic treatment with maintenance OCS for >/=6 months prior to Visit 1
  • Assessment to ensure diagnosis of asthma and OCS dependence on minimal effective or maximum tolerated dose prior to Visit 1 with compliance

Exclusion criteria

Exclusion Criteria:

  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Asthma exacerbation within 28 days prior to Visit 1 or during screening (prior to Visit 3)
  • For adults: Active tuberculosis requiring treatment within the 12 months prior to Visit 1
  • For adolescents: History of active tuberculosis requiring treatment
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • Known current or current evaluation for a potential malignancy
  • History of interstitial lung disease, , or other lung disease other than asthma
  • Infection requiring hospital admission or requiring treatment with intravenous (IV) or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening
  • Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
  • Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
  • Current smoker or former smoker with a smoking history of more than 15 pack-years
  • Current use of an immunomodulatory/ therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to Visit 1
  • Use of a licensed or monoclonal antibody other than anti-interleukin (IL)-13 or anti-IL-4/IL-13, including but not limited to, omalizumab, anti-IL-5, or anti-IL-17, within 6 months or 5 drug half-lives (whichever is longer) prior to Visit 1
  • Receipt of a within the 4 weeks prior to Visit 1 during screening or anticipation of receipt of a live attenuated vaccine throughout the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Lebrikizumab High Dose

    Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab Low Dose

    Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.

    Drug: Lebrikizumab · Drug: Placebo

Interventions

  • Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.

    Also known as: RO5490255

  • DrugPlacebo

    Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44

    OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an electronic diary (eDiary) on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the electronic Case Report Form (eCRF). Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post-baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (post-baseline value - baseline value)/baseline value \* 100.

    Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)

Secondary outcomes

  1. Absolute Change From Baseline in Daily OCS Dose at Week 44

    OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint.

    Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)

  2. Percent Change From Week 12 in Daily OCS Dose at Week 44

    OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. OCS dose at a timepoint was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (value at Week 44 - value at Week 12)/value at Week 12 \* 100. Reported values are adjusted mean values obtained from MMRM analysis.

    Time frame: Week 12 (including 28 days prior to Week 12), Week 44 (including 28 days prior to Week 44)

  3. Percentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline

    OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. The 95% confidence interval (CI) for the percentage was based on normal approximation for binomial proportion.

    Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)

  4. Percentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 44

    Percentage of participants who either discontinued OCS therapy or have achieved an adrenal maintenance dose is reported. Identification of participants achieving adrenal maintenance dose was based on physician assessment recorded in eCRF in the presence of cortisol = 100 nanomoles per liter (nmol/L). The 95% CI for the percentage was based on normal approximation for binomial proportion.

    Time frame: Week 44

  5. Rate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period

    An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.

    Time frame: Baseline up to Week 44

07

Results

Posted Nov 10, 2026
Limitations and caveats
The enrollment was closed, and dosing was terminated in this study following the sponsor's decision to discontinue development of lebrikizumab. Thus, this study was treated as exploratory (rather than confirmatory).

Participant flow

Participant flow — Overall Study
MilestonePlaceboLebrikizumab 125 mgLebrikizumab 250 mgPlacebo/Lebrikizumab 125 mgPlacebo/Lebrikizumab 250 mg
Started5656722422
Completed4839511819
Not completed8172163
Withdrew: Adverse event01000
Withdrew: Study terminated by sponsor11310
Withdrew: Withdrawal by subject5101642
Withdrew: Physician decision10100
Withdrew: Lost to follow-up10000
Withdrew: Non-compliance01100
Withdrew: Other04011

Outcome measures

PrimaryPercent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44

OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an electronic diary (eDiary) on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the electronic Case Report Form (eCRF). Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post-baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (post-baseline value - baseline value)/baseline value \* 100.

Time frame:
Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Reported as:
Mean · percent change
Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44
percent changePlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44-36.4 ± 5.99-42.9 ± 8.69-38.6 ± 7.24
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: -6.5 · 95% CI -27.2 to 14.3
  • Placebo vs Lebrikizumab 250 mg · Difference in adjusted means: -2.2 · 95% CI -20.7 to 16.3
SecondaryAbsolute Change From Baseline in Daily OCS Dose at Week 44

OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint.

Time frame:
Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Reported as:
Mean · mg
Absolute Change From Baseline in Daily OCS Dose at Week 44
mgPlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Absolute Change From Baseline in Daily OCS Dose at Week 44-5.2 ± 0.82-6.6 ± 1.18-5.8 ± 0.99
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: -1.5 · 95% CI -4.3 to 1.4
  • Placebo vs Lebrikizumab 250 mg · Difference in adjusted means: -0.6 · 95% CI -3.1 to 1.9
SecondaryPercent Change From Week 12 in Daily OCS Dose at Week 44

OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. OCS dose at a timepoint was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (value at Week 44 - value at Week 12)/value at Week 12 \* 100. Reported values are adjusted mean values obtained from MMRM analysis.

Time frame:
Week 12 (including 28 days prior to Week 12), Week 44 (including 28 days prior to Week 44)
Reported as:
Least squares mean · percent change
Percent Change From Week 12 in Daily OCS Dose at Week 44
percent changePlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Percent Change From Week 12 in Daily OCS Dose at Week 44-36.3 ± 5.69-44.0 ± 8.47-37.8 ± 6.97
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: -7.7 · 95% CI -27.3 to 11.9
  • Placebo vs Lebrikizumab 250 mg · Difference in adjusted means: -1.5 · 95% CI -18.6 to 15.7
SecondaryPercentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline

OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. The 95% confidence interval (CI) for the percentage was based on normal approximation for binomial proportion.

Time frame:
Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline
percentage of participantsPlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Percentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline39.6 ± 29.830.4 ± 18.340.9 ± 29.0
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Difference in percentage: -9.2 · 95% CI -24.7 to 6.3
  • Placebo vs Lebrikizumab 250 mg · Difference in percentage: 1.3 · 95% CI -14 to 16.7
SecondaryPercentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 44

Percentage of participants who either discontinued OCS therapy or have achieved an adrenal maintenance dose is reported. Identification of participants achieving adrenal maintenance dose was based on physician assessment recorded in eCRF in the presence of cortisol = 100 nanomoles per liter (nmol/L). The 95% CI for the percentage was based on normal approximation for binomial proportion.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Percentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 44
percentage of participantsPlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Percentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 4411.5 ± 5.110.7 ± 2.69.1 ± 2.2
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Difference in percentage: -0.7 · 95% CI -11.1 to 9.6
  • Placebo vs Lebrikizumab 250 mg · Difference in percentage: -2.4 · 95% CI -11.8 to 7.1
SecondaryRate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period

An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.

Time frame:
Baseline up to Week 44
Reported as:
Number · events per patient year
Rate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period
events per patient yearPlaceboLebrikizumab 125 mgLebrikizumab 250 mg
Rate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period1.781.541.47
Statistical analysis
  • Placebo vs Lebrikizumab 125 mg · Adjusted rate ratio: 0.86 · 95% CI 0.55 to 1.36
  • Placebo vs Lebrikizumab 250 mg · Adjusted rate ratio: 0.83 · 95% CI 0.57 to 1.21

Adverse events

Collected over Placebo group: from first dose of study treatment up to Week 44; Placebo/Lebrikizumab 125 mg and 250 mg groups: from Week 45 (first dose of lebrikizumab) up to end of treatment extension (up to 83 weeks); Lebrikizumab 125 mg and 250 mg groups: from first dose of study treatment up to end of treatment extension (up to 120 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/102 (0%)21/102 (20.6%)82/102 (80.4%)
Placebo/Lebrikizumab 125 mg0/24 (0%)4/24 (16.7%)22/24 (91.7%)
Placebo/Lebrikizumab 250 mg0/22 (0%)1/22 (4.5%)19/22 (86.4%)
Lebrikizumab 125 mg1/56 (1.8%)6/56 (10.7%)47/56 (83.9%)
Lebrikizumab 250 mg0/72 (0%)27/72 (37.5%)60/72 (83.3%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventPlaceboPlacebo/Lebrikizumab 125 mgPlacebo/Lebrikizumab 250 mgLebrikizumab 125 mgLebrikizumab 250 mg
AsthmaRespiratory, thoracic and mediastinal disorders11/1020/240/220/5610/72
Anaphylactic reactionImmune system disorders0/1020/241/221/560/72
GastritisGastrointestinal disorders0/1021/240/220/560/72
VomitingGastrointestinal disorders0/1021/240/220/560/72
Postoperative renal failureInjury, poisoning and procedural complications0/1021/240/220/560/72
HaemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1021/240/220/560/72
HeadacheNervous system disorders0/1021/240/220/560/72
ParaesthesiaNervous system disorders0/1021/240/220/560/72
SpondylolisthesisMusculoskeletal and connective tissue disorders0/1021/240/220/560/72
ColitisGastrointestinal disorders0/1020/240/220/562/72
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPlaceboPlacebo/Lebrikizumab 125 mgPlacebo/Lebrikizumab 250 mgLebrikizumab 125 mgLebrikizumab 250 mg
AsthmaRespiratory, thoracic and mediastinal disorders71/10214/2416/2238/5647/72
Lower respiratory tract infectionInfections and infestations25/1028/2414/227/5627/72
ArthralgiaMusculoskeletal and connective tissue disorders8/1024/248/223/5610/72
FallInjury, poisoning and procedural complications1/1020/245/220/565/72
Pain in extremityMusculoskeletal and connective tissue disorders2/1021/244/223/563/72
HeadacheNervous system disorders11/1022/241/226/5613/72
NasopharyngitisInfections and infestations7/1024/241/228/568/72
CoughRespiratory, thoracic and mediastinal disorders5/1024/243/222/566/72
BronchitisInfections and infestations5/1020/241/229/561/72
Peripheral swellingGeneral disorders2/1020/243/220/563/72

Baseline characteristics

The modified intent-to-treat (miTT) population included all participants who were randomized and received at least one dose of study drug (lebrikizumab or placebo).

Age, Continuous
Age, Continuous(years)PlaceboLebrikizumab 125 mgLebrikizumab 250 mgTotal
Mean49.1 ± 14.054.2 ± 12.249.1 ± 15.550.3 ± 14.2
Age, Customized
Age, Customized(Participants)PlaceboLebrikizumab 125 mgLebrikizumab 250 mgTotal
12 to < 1860612
18 to < 3052310
30 to < 5030122163
50 to < 65513234117
> = 651010828
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLebrikizumab 125 mgLebrikizumab 250 mgTotal
Female553644135
Male47202895
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLebrikizumab 125 mgLebrikizumab 250 mgTotal
Hispanic or Latino52512
Not Hispanic or Latino975467218
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLebrikizumab 125 mgLebrikizumab 250 mgTotal
American Indian or Alaska Native0000
Asian61613
Native Hawaiian or Other Pacific Islander0000
Black or African American2103
White915464209
More than one race3014
Unknown or Not Reported0011
08

Study locations

45 sites
  • Allergy & Asthma Care Center of Southern California
    Long Beach, California 90808, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Monash Medical Centre; Respiratory and Sleep Medicine
    Clayton, Victoria 3168, Australia
  • Institute for Respiratory Health Inc
    Nedlands, Western Australia 6009, Australia
  • UZ Gent
    Ghent, 9000, Belgium
  • Nemocnice Liberec; KNL a.s. - TRN
    Liberec, 460 63, Czechia
  • Nemocnice Nový Ji?ín
    Nový Ji?ín, 741-01, Czechia
  • Rokycanska nemocnice
    Rokycany, 337 22, Czechia
  • Gentofte Hospital, Klinik for Allergi
    Hellerup, 2900, Denmark
  • CH de Bicetre; Pneumologie
    Le Kremlin-Bicêtre, 94275, France
  • Hôpital de La Croix Rousse
    Lyon, 69004, France
  • Hôpital Arnaud de Villeneuve
    Montpellier, 34295, France
  • CHU Nantes - Hôpital Laennec; Service de Pneumologie
    Nantes, 44093, France
  • CHU de Nice; Service Système Nerveux Périphérique
    Nice, 06001, France
  • Hopital Bichat Claude Bernard ; Service de Pneumologie
    Paris, 75877, France
  • Centro Investigacion Medico Biologica y Terapia Avanzada
    Guadalajara, 44130, Mexico
  • Centro Integral Médico SJR SC
    Querétaro, 76800, Mexico
  • Academisch Medisch Centrum; Afdeling Longziekten, F5-258
    Amsterdam, 1105 AZ, Netherlands
  • Dunedin Hospital
    Dunedin, New Zealand
  • Clinical Trials Unit, Bay of Plenty District Health Board
    Tauranga, 3143, New Zealand
  • Medical Research Inst. of New Zealand; Respiratory
    Wellington, New Zealand
  • Malopolskie Centrum Alergologii
    Krakow, 30-727, Poland
  • Specjalistyczny Osrodek Alergologiczno-Internistyczny ALL-MED
    Krakow, 31-024, Poland
  • Klinika Chorób Wewnetrznych i Alergologii MSW
    Warsaw, 02-507, Poland
  • EMC Przychodnia przy ul. Lowieckie; Przychodnia przy ulicy Lowieckiej
    Wroc?aw, 50-220, Poland
  • San Juan Bautista School of Medicine-Clinical Research Unit
    Caguas, 00725, Puerto Rico
  • ZAPA JJ Sro
    Levice, 934 01, Slovakia
  • Plucna ambulancia
    Spišská Nová Ves, 052 01, Slovakia
  • University Clinic of Pulmonary and Allergic Diseases Golnik
    Golnik, 4204, Slovenia
  • Complejo Hospitalario Universitario de Santiago; Servicio de Neumología
    Santiago de Compostela, LA Coruña 15706, Spain
  • Hospital Clinico Universitario de Salamanca; Servicio de Neumologia
    Salamanca, 37007, Spain
  • Hospital Universitario Doctor Peset
    Valencia, 46017, Spain
  • Belfast City Hospital; Respiratory Department
    Belfast, BT9 7AB, United Kingdom
  • Heartlands Hospital; Respiratory Department
    Birmingham, B9 5SS, United Kingdom
  • Gartnavel General Hospital; Respiratory Department
    Glasgow, G12 0YN, United Kingdom
  • New Lister Buliding, Level 1; Clinical Research Facility
    Glasgow, G31 2ER, United Kingdom
  • Southampton General Hospital; Respiratory Department
    Hampshire, SO16 6YD, United Kingdom
  • Leicester Royal Infirmary NHS Trust
    Leicester, LE1 5WW, United Kingdom
  • Glenfield Hospital; Respiratory -Allergy Unit
    Leicester, LE3 9QP, United Kingdom
  • St Bartholomew's Hospital (Barts); Respiratory Department
    London, EC1A 7BE, United Kingdom
  • Royal Brompton Hospital; Respiratory Department
    London, SW3 6NP, United Kingdom
  • Wythenshawe Hospital; North West Lung Research Centre
    Manchester, M23 9LT, United Kingdom
  • Freeman Hospital; Respiratory Department
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Derriford Hospital; The Lind Research Department
    Plymouth, PL6 8DH, United Kingdom
  • Sheffield Clinical Research Facility; National Institute for Health Research
    Sheffield, S10 2JF, United Kingdom
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Dec 2016, 33 months.

Results were first posted in Nov 2026, 9 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Nov 19, 2013
StartActual
Feb 21, 2014
Primary completionActual
Dec 19, 2016
CompletionActual
Dec 19, 2016
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
changed Nov 10, 2026
Results
Results posted
posted Nov 10, 2026
Sites
9 sites added, 35 sites removed; no longer in Canada
Show 9 added (2 Czechia, 2 France, 2 Poland, 1 Belgium, 1 Slovakia, 1 Spain)
  • UZ Gent · Ghent, Belgium
  • Nemocnice Liberec; KNL a.s. - TRN · Liberec, Czechia
  • Nemocnice Nový Ji?ín · Nový Ji?ín, Czechia
  • CH de Bicetre; Pneumologie · Le Kremlin-Bicêtre, France
  • CHU de Nice; Service Système Nerveux Périphérique · Nice, France
  • Klinika Chorób Wewnetrznych i Alergologii MSW · Warsaw, Poland
  • EMC Przychodnia przy ul. Lowieckie; Przychodnia przy ulicy Lowieckiej · Wroc?aw, Poland
  • Plucna ambulancia · Spišská Nová Ves, Slovakia
  • Complejo Hospitalario Universitario de Santiago; Servicio de Neumología · Santiago de Compostela, Spain
Show 35 removed
  • Kern Allergy Med Clinic, Inc. · Bakersfield, United States
  • South Florida Research Center, Inc. · Miami, United States
  • Georgia Pollens · Albany, United States
  • Mount Sinai Medical Center · New York, United States
  • Allergy & Immunology · Tulsa, United States
  • Pioneer Research Solutions · Houston, United States
  • Pulmonary Consultants PLLC · Tacoma, United States
  • Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine · Brisbane, Australia
  • Clin Univ de Bxl Hôpital Erasme · Bruxelles, Belgium
  • Longartsenpraktijk · Genk, Belgium
  • UZ Gent · Gent, Belgium
  • Inspiration Research Limited · Toronto, Canada
  • Hornmed · Brno, Czechia
  • Nemocnice Liberec; KNL a.s. - TRN · Liberec 1, Czechia
  • Nemocnice Nový Jičín · Nový Jičín, Czechia
  • CHU de Grenoble - Hôpital André Michallon · Grenoble Cedex 9, France
  • CH de Bicetre; Pneumologie · Le Kremlin Bicetre, France
  • CHU de Nice · Nice Cedex 1, France
  • CHU de Haut Leveque · Pessac, France
  • Nouvel Hôpital Civil; Pôle de Pathologie Thoracique · Strabourg, France
  • Instituto Jalisciense de Investigacion Clinica S.A. de C.V. · Guadalajara, Mexico
  • Spaarne Ziekenhuis Hoofddorp; Long Geneeskunde · Hoofddorp, Netherlands
  • Antonius Ziekenhuis; Dept of Lung Diseases · Nieuwegein, Netherlands
  • NZ Respiratory & Sleep Institute · Auckland, New Zealand
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi · Lodz, Poland
  • Specjalistyczna Poradnia Pulmonologiczna · Ostrow Wielkopolski, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA Wladyslaw Pierzchala · Ruda Śląska, Poland
  • Klinika Chorób Wewnetrznych i Alergologii MSW · Warszawa, Poland
  • EMC Instytut Medyczny SA; Przychodnia przy ulicy Łowieckiej · Wrocław, Poland
  • Advanced Medical Concepts, PSC · Cidra, Puerto Rico
  • …and 5 more on the registry record
Nov 10, 2026
Start date
Feb 28, 2014→Feb 21, 2014
Nov 10, 2026
Primary completion
Dec 20, 2016→Dec 19, 2016
Nov 10, 2026
Study completion
Dec 20, 2016→Dec 19, 2016
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRelativePercent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44Time frame: Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Nov 10, 2026
Secondary outcomes
3 edited, 1 time frame changed, 1 added, 4 removed, 1 description edited
What changed in the outcomes
  • EditedRelativePercent Change From Week 12 in AverageDaily OCS Dose at Week 44Time frame: Week 12, Week 44 → Week 12 (including 28 days prior to Week 12), Week 44 (including 28 days prior to Week 44)
  • EditedPercentage of Participants AchievingWho Achieved at Least a 50 percentPercent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to BaselineTime frame: Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
  • EditedPercentage of Participants DiscontinuingWho Either Discontinued OCS Therapy or Having Achieved an Adrenal Maintenance Dose at Week 44Time frame: Week 44
  • AddedRate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) PeriodTime frame: Baseline up to Week 44
  • RemovedPercentage of Participants With Asthma ExacerbationsTime frame: Baseline up to Week 44
  • RemovedPercentage of Participants With Adverse EventsTime frame: Baseline up to 24 weeks after last dose administration (up to a minimum of approximately 2 years)
  • RemovedPercentage of Participants With Anti-therapeutic Antibodies (ATAs) Against LebrikizumabTime frame: Predose (0 hours) at Weeks 0, 4, 12, 24, 36, 44, 52, 64, and 76, at early discontinuation (up to a minimum of approximately 2 years), and at 24 weeks after last dose administration (up to a minimum of approximately 2 years)
  • RemovedMinimum Observed Serum Lebrikizumab Concentration (Cmin)Time frame: Predose (0 hours) at Weeks 4, 12, 24, 36, and 44
  • Time frameAbsolute Change From Baseline in Daily OCS Dose at Week 44Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
  • DescriptionAbsolute Change From Baseline in Daily OCS Dose at Week 44: how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Completed→Terminated
    Why stopped Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
    Results posted
    9 sites added, 35 sites removed; no longer in Canada
    Show 9 added (2 Czechia, 2 France, 2 Poland, 1 Belgium, 1 Slovakia, 1 Spain)
    • UZ Gent · Ghent, Belgium
    • Nemocnice Liberec; KNL a.s. - TRN · Liberec, Czechia
    • Nemocnice Nový Ji?ín · Nový Ji?ín, Czechia
    • CH de Bicetre; Pneumologie · Le Kremlin-Bicêtre, France
    • CHU de Nice; Service Système Nerveux Périphérique · Nice, France
    • Klinika Chorób Wewnetrznych i Alergologii MSW · Warsaw, Poland
    • EMC Przychodnia przy ul. Lowieckie; Przychodnia przy ulicy Lowieckiej · Wroc?aw, Poland
    • Plucna ambulancia · Spišská Nová Ves, Slovakia
    • Complejo Hospitalario Universitario de Santiago; Servicio de Neumología · Santiago de Compostela, Spain
    Show 35 removed
    • Kern Allergy Med Clinic, Inc. · Bakersfield, United States
    • South Florida Research Center, Inc. · Miami, United States
    • Georgia Pollens · Albany, United States
    • Mount Sinai Medical Center · New York, United States
    • Allergy & Immunology · Tulsa, United States
    • Pioneer Research Solutions · Houston, United States
    • Pulmonary Consultants PLLC · Tacoma, United States
    • Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine · Brisbane, Australia
    • Clin Univ de Bxl Hôpital Erasme · Bruxelles, Belgium
    • Longartsenpraktijk · Genk, Belgium
    • UZ Gent · Gent, Belgium
    • Inspiration Research Limited · Toronto, Canada
    • Hornmed · Brno, Czechia
    • Nemocnice Liberec; KNL a.s. - TRN · Liberec 1, Czechia
    • Nemocnice Nový Jičín · Nový Jičín, Czechia
    • CHU de Grenoble - Hôpital André Michallon · Grenoble Cedex 9, France
    • CH de Bicetre; Pneumologie · Le Kremlin Bicetre, France
    • CHU de Nice · Nice Cedex 1, France
    • CHU de Haut Leveque · Pessac, France
    • Nouvel Hôpital Civil; Pôle de Pathologie Thoracique · Strabourg, France
    • Instituto Jalisciense de Investigacion Clinica S.A. de C.V. · Guadalajara, Mexico
    • Spaarne Ziekenhuis Hoofddorp; Long Geneeskunde · Hoofddorp, Netherlands
    • Antonius Ziekenhuis; Dept of Lung Diseases · Nieuwegein, Netherlands
    • NZ Respiratory & Sleep Institute · Auckland, New Zealand
    • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi · Lodz, Poland
    • Specjalistyczna Poradnia Pulmonologiczna · Ostrow Wielkopolski, Poland
    • Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA Wladyslaw Pierzchala · Ruda Śląska, Poland
    • Klinika Chorób Wewnetrznych i Alergologii MSW · Warszawa, Poland
    • EMC Instytut Medyczny SA; Przychodnia przy ulicy Łowieckiej · Wrocław, Poland
    • Advanced Medical Concepts, PSC · Cidra, Puerto Rico
    • …and 5 more on the registry record
    Start date Feb 28, 2014→Feb 21, 2014
    Primary completion Dec 20, 2016→Dec 19, 2016
    Study completion Dec 20, 2016→Dec 19, 2016
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRelativePercent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44Time frame: Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
    Secondary outcomes 3 edited, 1 time frame changed, 1 added, 4 removed, 1 description edited
    What changed in the outcomes
    • EditedRelativePercent Change From Week 12 in AverageDaily OCS Dose at Week 44Time frame: Week 12, Week 44 → Week 12 (including 28 days prior to Week 12), Week 44 (including 28 days prior to Week 44)
    • EditedPercentage of Participants AchievingWho Achieved at Least a 50 percentPercent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to BaselineTime frame: Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
    • EditedPercentage of Participants DiscontinuingWho Either Discontinued OCS Therapy or Having Achieved an Adrenal Maintenance Dose at Week 44Time frame: Week 44
    • AddedRate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) PeriodTime frame: Baseline up to Week 44
    • RemovedPercentage of Participants With Asthma ExacerbationsTime frame: Baseline up to Week 44
    • RemovedPercentage of Participants With Adverse EventsTime frame: Baseline up to 24 weeks after last dose administration (up to a minimum of approximately 2 years)
    • RemovedPercentage of Participants With Anti-therapeutic Antibodies (ATAs) Against LebrikizumabTime frame: Predose (0 hours) at Weeks 0, 4, 12, 24, 36, 44, 52, 64, and 76, at early discontinuation (up to a minimum of approximately 2 years), and at 24 weeks after last dose administration (up to a minimum of approximately 2 years)
    • RemovedMinimum Observed Serum Lebrikizumab Concentration (Cmin)Time frame: Predose (0 hours) at Weeks 4, 12, 24, 36, and 44
    • Time frameAbsolute Change From Baseline in Daily OCS Dose at Week 44Baseline, Week 44 → Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
    • DescriptionAbsolute Change From Baseline in Daily OCS Dose at Week 44: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01987492
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Feb 21, 2014
Primary completion
Dec 19, 2016
Completion
Dec 19, 2016
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion